CRTPF News and Press, Cardiol Therapeutics From 03/30/21

Cardiol Therapeutics (CRTPF) appointed 30-years industry veteran Dr. Andrew Hamer as chief medical officer, effective immediately, leading the R&D of the company's clinical-stage products and also guiding the development of additional novel therapeutics in the company'...

Oakville, Ontario--(Newsfile Corp. - March 30, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) ( FSE: CT9 ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of ca...

NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the March 25 th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and in...

NEW YORK , March 19, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations an...

Oakville, Ontario--(Newsfile Corp. - March 2, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) ( FSE: CT9 ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascula...

Cardiol Therapeutics (CRTPF) announces the formation of Data Safety Monitoring Committee ((DSMC)) and the Clinical Endpoint Committees ((CEC)) for the company's Phase II/III trial in high-risk patients hospitalized with COVID-19 at clinical centers throughout the United States.The DSMC c...

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease Oakville, Ontario--(Newsfile Corp. - January 21, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( ...

Oakville, Ontario--(Newsfile Corp. - January 7, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, announced today that David Elsl...

Study results are expected to support the Company's plans to file an IND application with the FDA for a Phase II clinical trial in acute myocarditis Oakville, Ontario--(Newsfile Corp. - December 22, 2020) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) (" Cardiol " or the " Compa...

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease now being initiated at clinical centers in the United States Oakville, Ontario--(Newsfile Corp. - Dec...